Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel Samnick

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Clinical Nuclear Medicine|March 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Oncotarget|February 5, 2016
[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experienceConstantin Lapa, Katharina Lückerath, Martina Rudelius, et al.
Theranostics|January 3, 2017
[<sup>68</sup>Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [<sup>18</sup>F]FDG and laboratory valuesConstantin Lapa, Martin Schreder, Andreas Schirbel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 20, 2018
Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell LymphomaConstantin Lapa, Heribert Hänscheid, Malte Kircher, et al.
Frontiers in Nuclear Medicine|October 2, 2024
Molecular Imaging in Multiple Myeloma-Novel PET Radiotracers Improve Patient Management and Guide TherapyJohannes von Hinten, Malte Kircher, Alexander Dierks, et al.
Molecular Imaging and Biology|April 13, 2019
Prognostic Value of O-(2-[<sup>18</sup>F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III GliomaOlivia Kertels, Almuth F Kessler, Milena I Mihovilovic, et al.
Arthritis Research & Therapy|February 11, 2026
Establishing C-X-C motif chemokine receptor 4 as a novel imaging target in giant cell arteritisMatthias Fröhlich, Sebastian E Serfling, Michael Gernert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 16, 2014
Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patientsConstantin Lapa, Thomas Linsenmann, Camelia Maria Monoranu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 23, 2022
C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell LymphomaAndreas K Buck, Götz Ulrich Grigoleit, Sabrina Kraus, et al.
Experimental Neurology|January 28, 2015
Fullerenols and glucosamine fullerenes reduce infarct volume and cerebral inflammation after ischemic stroke in normotensive and hypertensive ratsFelix Fluri, Dan Grünstein, Ertugrul Cam, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Clinical Nuclear Medicine|March 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Oncotarget|February 5, 2016
[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experienceConstantin Lapa, Katharina Lückerath, Martina Rudelius, et al.
Theranostics|January 3, 2017
[<sup>68</sup>Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [<sup>18</sup>F]FDG and laboratory valuesConstantin Lapa, Martin Schreder, Andreas Schirbel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 20, 2018
Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell LymphomaConstantin Lapa, Heribert Hänscheid, Malte Kircher, et al.
Frontiers in Nuclear Medicine|October 2, 2024
Molecular Imaging in Multiple Myeloma-Novel PET Radiotracers Improve Patient Management and Guide TherapyJohannes von Hinten, Malte Kircher, Alexander Dierks, et al.
Molecular Imaging and Biology|April 13, 2019
Prognostic Value of O-(2-[<sup>18</sup>F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III GliomaOlivia Kertels, Almuth F Kessler, Milena I Mihovilovic, et al.
Arthritis Research & Therapy|February 11, 2026
Establishing C-X-C motif chemokine receptor 4 as a novel imaging target in giant cell arteritisMatthias Fröhlich, Sebastian E Serfling, Michael Gernert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 16, 2014
Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patientsConstantin Lapa, Thomas Linsenmann, Camelia Maria Monoranu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 23, 2022
C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell LymphomaAndreas K Buck, Götz Ulrich Grigoleit, Sabrina Kraus, et al.
Experimental Neurology|January 28, 2015
Fullerenols and glucosamine fullerenes reduce infarct volume and cerebral inflammation after ischemic stroke in normotensive and hypertensive ratsFelix Fluri, Dan Grünstein, Ertugrul Cam, et al.
Pageof 10